New injection tested for stubborn shoulder pain
NCT ID NCT05569174
Summary
This study tested whether an injectable drug called secukinumab could reduce pain and improve function in adults with moderate-to-severe shoulder tendon pain that hadn't gotten better with standard treatments like painkillers and physical therapy. For 24 weeks, 62 participants received either the drug or a placebo injection, along with personalized physical therapy. The main goal was to see if the drug led to better shoulder function and less pain compared to the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENDINOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hamburg, 20149, Germany
-
Novartis Investigative Site
Hamburg, 22415, Germany
-
Novartis Investigative Site
Heinsberg, 52525, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Schönebeck, 39218, Germany
-
Novartis Investigative Site
Hamburg, 20095, Germany
-
Novartis Investigative Site
Karlsruhe, Baden-Wurttemberg, 76133, Germany
-
Novartis Investigative Site
Munich, Bavaria, 80809, Germany
-
Novartis Investigative Site
Hanover, Lower Saxony, 30159, Germany
-
Novartis Investigative Site
Halle, Saxony-Anhalt, 06120, Germany
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 10787, Germany
-
Novartis Investigative Site
Berlin, 12627, Germany
-
Novartis Investigative Site
Cottbus, 03042, Germany
-
Novartis Investigative Site
Dresden, 01069, Germany
-
Novartis Investigative Site
Erlangen, 91054, Germany
-
Novartis Investigative Site
Frankfurt am Main, 60313, Germany
-
Novartis Investigative Site
Gladbeck, 45968, Germany
Conditions
Explore the condition pages connected to this study.